Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $282
Jazz Pharmaceuticals Public Limited Company
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:
JAZZ) with a Buy and raises the price target from $255 to $282.